Low-Dose Aripiprazole for Long COVID

Introduction

Long COVID — the persistence of symptoms beyond the acute phase of SARS-CoV-2 infection — affects an estimated 10–30% of COVID-19 survivors. Among the most debilitating and least understood symptom clusters are neurological manifestations: cognitive dysfunction ("brain fog"), fatigue, sleep disturbance, and autonomic dysregulation.

This article examines the emerging rationale for low-dose aripiprazole as a potential intervention for neuroinflammatory components of long COVID.

Context

Aripiprazole is an atypical antipsychotic that functions as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A receptors. At low doses (1–2 mg), its pharmacological profile shifts toward anti-inflammatory and neuroprotective effects, with reduced conventional antipsychotic activity.

The neuroinflammatory hypothesis of long COVID posits that persistent microglial activation, blood-brain barrier dysfunction, and dysregulated cytokine signaling contribute to the neurological symptom burden. Low-dose aripiprazole's ability to modulate microglial activation through partial D2 agonism has generated interest as a potential therapeutic approach.

Analysis

The evidence base for this application remains preliminary:

• Preclinical data: Animal models demonstrate that low-dose aripiprazole reduces microglial activation markers and neuroinflammatory cytokine production
• Case series: Small, uncontrolled case series have reported symptom improvement in long COVID patients treated with low-dose aripiprazole, particularly for cognitive dysfunction and fatigue
• Mechanistic plausibility: The drug's unique receptor pharmacology at low doses aligns with the neuroinflammatory hypothesis, but mechanism-based reasoning has a historically poor track record of predicting clinical efficacy

Limitations

1. No randomized controlled trial data currently exists for this indication
2. Placebo effects are substantial in symptom-based conditions, making uncontrolled observations unreliable
3. Off-label use raises ethical and regulatory considerations
4. Heterogeneity of long COVID presentations means that even if effective, it may only benefit a subset of patients

Clinical Implications

This intervention should be considered investigational. Clinicians considering off-label use should ensure informed consent, document outcomes systematically, and report results to contribute to the evidence base.

The appropriate next step is a well-designed, adequately powered randomized controlled trial with validated cognitive and fatigue outcome measures.

Conclusion

Low-dose aripiprazole represents a mechanistically plausible but clinically unproven intervention for neuroinflammatory symptoms in long COVID. The gap between biological rationale and clinical evidence must be closed through rigorous clinical trials before this approach can be recommended. Promising case reports are hypothesis-generating, not practice-changing.